What transplant eligibility restriction applies to polatuzumab vedotin's licensed use in adults with relapsed or refractory diffuse large B-cell lymphoma?

Polivy (polatuzumab vedotin), combined with bendamustine and rituximab, is indicated for adults with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for haematopoietic stem cell transplant.